Efficacy and Safety of Peginterferon in ET and PV.

A Single-arm, Single-center Study to Explore the Safety and Efficacy of Pegylated Interferon Alpha in Chinese Patients With ET (Essential Thrombocythemia) and PV (Polycythemia Vera).

This is a single-arm, single-center study aims to recruit 40 participants with Essential Thrombocythemia (ET) and Polycythemia Vera (PV). Eligible participants will receive a subcutaneous injection of Peginterferon α-2b 180 mcg once a week and follow-up，and efficacy and safety will be evaluated.

Study Overview

• Status: Recruiting
• Conditions: Polycythemia Vera; Essential Thrombocythemia
• Intervention / Treatment: Drug: Peginterferon α-2b injection

• Study Type: Interventional
• Enrollment (Estimated): 40
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: ZhenYa Hong, Ph.D; Phone Number: 13476158466; Email: hongzhenya@126.com

Study Locations

• China
  • Hubei
    • Wuhan, Hubei, China
      • Recruiting
      • Tongji Medical College, Huazhong University of Science and Technology
      • Contact: ZhenYa Hong; Phone Number: 13476158466; Email: hongzhenya@126.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Meet the 2016 WHO diagnostic criteria for ET (Essential Thrombocythemia) and PV (Polycythemia Vera)

   • ET (Essential Thrombocythemia) major criteria:

     1. Platelet count > 450 * 10^9/L; (2) Bone marrow biopsy shows marked megakaryocytic proliferation with increased mature megakaryocyte volume and increased nuclear lobulation. There is no significant granulocytic proliferation, left shift, or erythroid proliferation, with grade 1 fibrosis observed in a few cases; (3) Does not meet the WHO diagnostic criteria for BCR-ABL1+ CML, PV, PMF, MDS, or other myeloproliferative neoplasms; (4) JAK2, CALR, or MPL mutation positive.

        Secondary criteria: (1) Presence of a clonal marker or absence of evidence for reactive thrombocytosis.

        The diagnosis of ET requires the fulfillment of all four main criteria, or the first three main criteria plus one secondary criterion.

   • PV (Polycythemia Vera) main criteria: (1) Hemoglobin > 16.5 g/dL in males, > 16 g/dL in females, or Hematocrit > 49% in males, > 48% in females, or an increase in red cell volume of 25% or more above the normal value; (2) Bone marrow biopsy shows increased cellularity inappropriate for age, with marked erythroid, granulocytic, and megakaryocytic proliferation, and the presence of mature megakaryocytes of varying sizes and morphologies; (3) JAK2 V617F mutation positive or JAK2 exon 12 mutation positive.

   Secondary criteria: Serum Epo (Erythropoietin) level below the lower limit of the normal range.

   The diagnosis of PV requires the fulfillment of three major criteria, or the first two main criteria plus one secondary criterion.

2. For ET patients, the criteria for cytoreductive therapy must be met, as follows:

(1) For patients without a history of thrombosis: Age ≥ 60 years, regardless of the presence of cardiovascular risk (CVR) or JAK2V617 mutation; Any age with a platelet count > 1500 × 109/L. (2) For patients with a history of arterial thrombosis: Any age, regardless of the presence of CVR and JAK2V617 mutation; (3) For patients with a history of venous thrombosis: Any age, regardless of the presence of CVR and JAK2V617 mutation; 3.ECOG score ≤ 2. 4.Cardiac ejection fraction (EF) ≥ 60%. 5.The participant voluntarily signs the informed consent form.

Exclusion Criteria:

• Previous treatment with Peginterferon α-2b.
• ET patients who do not meet the criteria for cytoreductive therapy as per the 2016 Chinese Expert Consensus on Primary Thrombocythemia.
• Allergy to the active ingredient, α-interferon, or any excipients of this product.
• History of psychiatric illness, or allergy to interferon.
• Plasma total bilirubin greater than twice the normal value.
• Severe cardiac disease, liver insufficiency, chronic kidney disease, and neurological disorders (such as depression or mania).
• History of other malignant tumors within the past three years.
• Autoimmune chronic hepatitis.
• Any condition deemed unsuitable for inclusion by the investigator.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Peginterferon α-2b	Drug: Peginterferon α-2b injection; Participants will receive Peginterferon α-2b 180 mcg once a week and follow-up. Dose adjustments will be made by the investigator based on the type and severity of adverse event (AE).

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Hematologic remission rate	Week 12,24

Secondary Outcome Measures

Outcome Measure	Time Frame
Molecular remission rate	Week 24,48
Peripheral blood driver genes	Week 24,48
Bone marrow-driven genes	Week 24,48
The incidence of thrombosis	Week 24,48
Incidence of bleeding events	Week 24,48
The incidence of progression to myelofibrosis.	Week 24,48
The incidence of acute leukemia.	Week 24,48
Changes in the burden of driver gene mutations during maintenance therapy.	Week 24,48
Hematologic remission	Week 48
Spleen enlargement remission rate.	Week 24,48

Collaborators and Investigators

• Sponsor: Zhenya Hong
• Investigators: Principal Investigator: ZhenYa Hong, Ph.D, Tongji Medical College, Huazhong University of Science and Technology

Study record dates

Study Major Dates

• Study Start (Actual): November 20, 2024
• Primary Completion (Estimated): November 20, 2026
• Study Completion (Estimated): November 20, 2027

Study Registration Dates

• First Submitted: December 11, 2024
• First Submitted That Met QC Criteria: December 11, 2024
• First Posted (Actual): March 25, 2025

Study Record Updates

• Last Update Posted (Actual): March 25, 2025
• Last Update Submitted That Met QC Criteria: December 11, 2024
• Last Verified: December 1, 2024

More Information

Terms related to this study

• Keywords: Polycythemia vera; Essential thrombocythemia; Peginterferon α-2b
• Additional Relevant MeSH Terms: Neoplasms by Site; Neoplasms; Hematologic Diseases; Blood Coagulation Disorders; Bone Marrow Diseases; Hemorrhagic Disorders; Blood Platelet Disorders; Myeloproliferative Disorders; Bone Marrow Neoplasms; Hematologic Neoplasms; Thrombocytosis; Thrombocythemia, Essential; Polycythemia Vera; Polycythemia
• Other Study ID Numbers: 2024S005

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No